Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2008

Aerovance Closes $10M Financing Round

  • Aerovance secured $20 million in venture debt financing. Aerovance says that it drew down $10 million from the financing line at closing. The remaining $10 million is available upon the achievement of corporate milestones.

    The money will support development of Aerovant, which is in Phase IIa studies for asthma. Aerovant is a recombinant human IL-4 variant that is an inhibitor of both the IL-4 and IL-13 receptors.

    Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »